[ CAS No. 58-64-0 ] {[proInfo.proName]}

Name: 58-64-0|Adenosine 5'-diphosphate|95%
Brand: Ambeed
SKU: A120434
Price: 12.0 USD
Availability: InStock
Rating: 94 (35 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 58-64-0 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 58-64-0 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 58-64-0 ]

SDS Specification

Alternatived Products of [ 58-64-0 ]

Product Details of [ 58-64-0 ]

CAS No. :	58-64-0	MDL No. :	MFCD00066473
Formula :	C₁₀H₁₅N₅O₁₀P₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	XTWYTFMLZFPYCI-KQYNXXCUSA-N
M.W :	427.20	Pubchem ID :	6022
Synonyms :	Adenosine diphosphate;ADP;Ado-5'-P-P;5′-ADP;adenosine pyrophosphate

Calculated chemistry of [ 58-64-0 ]

Physicochemical Properties

Num. heavy atoms :	27
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.5
Num. rotatable bonds :	6
Num. H-bond acceptors :	13.0
Num. H-bond donors :	6.0
Molar Refractivity :	84.49
TPSA :	252.22 Å²

Pharmacokinetics

GI absorption :	Low
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-12.19 cm/s

Lipophilicity

Log Po/w (iLOGP) :	-0.53
Log Po/w (XLOGP3) :	-4.62
Log Po/w (WLOGP) :	-2.06
Log Po/w (MLOGP) :	-4.15
Log Po/w (SILICOS-IT) :	-4.63
Consensus Log Po/w :	-3.2

Druglikeness

Lipinski :	2.0
Ghose :	None
Veber :	1.0
Egan :	1.0
Muegge :	4.0
Bioavailability Score :	0.11

Water Solubility

Log S (ESOL) :	0.57
Solubility :	1590.0 mg/ml ; 3.73 mol/l
Class :	Highly soluble
Log S (Ali) :	-0.05
Solubility :	378.0 mg/ml ; 0.884 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	2.15
Solubility :	59800.0 mg/ml ; 140.0 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	4.62

Safety of [ 58-64-0 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 58-64-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 58-64-0 ]
Downstream synthetic route of [ 58-64-0 ]

[ 58-64-0 ] Synthesis Path-Upstream 1~1

1
[ 53-84-9 ]
[ 1094-61-7 ]
[ 58-64-0 ]
[ 58-61-7 ]

Reference： [1] Patent: WO2017/145151, 2017, A1, . Location in patent: Page/Page column 28

[ 58-64-0 ] Synthesis Path-Downstream 1~76

1
[ 61-19-8 ]
[ 56-65-5 ]
[ 58-64-0 ]

Reference： [1]Methods in Enzymology,1955,vol. 2,p. 598
[2]Journal of Biological Chemistry,1960,vol. 235,p. 3260,3262
[3]Phytochemistry,1996,vol. 42,p. 589 - 594
[4]Journal of the American Chemical Society,2012,vol. 134,p. 16562 - 16570,9

2
[ 61-19-8 ]
[ 58-64-0 ]
[ 56-65-5 ]

Reference： [1]Tetrahedron Letters,1993,vol. 34,p. 4801 - 4804
[2]Chemistry Letters,1985,p. 985 - 988
[3]Chemistry Letters,1985,p. 985 - 988
[4]Journal of the American Chemical Society,1954,vol. 76,p. 3517,3521
[5]Tetrahedron Letters,1982,vol. 23,p. 5415 - 5418
[6]Journal of the American Chemical Society,1954,vol. 76,p. 3517,3521
[7]Antimicrobial Agents and Chemotherapy,1995,vol. 39,p. 2304 - 2308
[8]RSC Advances,2014,vol. 4,p. 2103 - 2108
[9]Patent: US2795580,1955,
[10]ChemBioChem,2019,vol. 20,p. 2961 - 2967

3
[ 56-65-5 ]
[ 58-64-0 ]

Yield	Reaction Conditions	Operation in experiment
	With (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; tris(3-hydroxypropyl)phosphine; nicotinamide phosphoribosyltransferase; water; tris hydrochloride; magnesium chloride; at 37℃;pH 7.5;Enzymatic reaction;Kinetics;	For the NTPase assays, NAMPT or NAMPT-H247A was incubated at 37 C with an NTP in TMT buffer (50 mM Tris-HCl, 10 mM MgC12, 1 mM THP, pH 7.5). The routinely-used NTP concentration was 2 mM. However, for the kinetic analysis <strong>[56-65-5]ATP</strong> and GTP hydrolysis, the NTP concentration ranged from 0.25 mM to 4 mM. Other agents (FK-866, CHS-828, GNI-50, PNP, NMN) were included where indicated. At the indicated times, an aliquot of the sample was quenched by the addition of an equal volume of 1 M perchloric acid (PCA). Samples were stored at -80 C until processed for LC/MS/MS. The values for Vmax and Km (<strong>[56-65-5]ATP</strong> and GTP hydrolysis) were deduced using the on-line Michaelis-Menten kinetics tool at (0160) http://www.graphpad.com/quickcalcs/ttestl/?Format=SEM For the NMN production assay, NAMPT (20 nM) was incubated in the presence of NAM (10 muMu), PRPP (50 muMu) in TMT buffer. Where indicated, NTPs (2 mM) were also included. NMN was assayed using a chemical method which converts NMN into a fluorescent derivative. Briefly, an aliquot (37.5 mu) of the NMN- containing sample was sequentially mixed with 15 mu of 20% acetophenone (in DMSO) and 15 mu of 2M KOH. The mixture was placed on ice for approximately 10 min. Next, 67.5 mu of 100% formic acid was added to each sample, vortexed, and then incubated at 37 C for 20 min. Samples (100 mu) were transferred to a 96-well opaque bottom plate and fluorescence (Ex/Em = 382/445 nm) was measured using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA).

Reference： [1]Journal of Organic Chemistry,1984,vol. 49,p. 1360 - 1364
[2]Biochemical Journal,1950,vol. 47,p. 105,107
[3]Biochemical Journal,1958,vol. 70,p. 222 - 230
[4]Biochemical Preparations,1949,vol. 1,p. 1
[5]Journal of the American Chemical Society,1987,vol. 109,p. 537 - 544
[6]Helvetica Chimica Acta,1983,vol. 66,p. 2454 - 2466
[7]Bioscience, Biotechnology and Biochemistry,1995,vol. 59,p. 1737 - 1739
[8]ACH - Models in Chemistry,1996,vol. 133,p. 365 - 388
[9]ACH - Models in Chemistry,1996,vol. 133,p. 65 - 81
[10]Russian Journal of Bioorganic Chemistry,2000,vol. 26,p. 474 - 481
[11]Bioscience, Biotechnology and Biochemistry,2001,vol. 65,p. 1379 - 1387
[12]Nucleosides, nucleotides and nucleic acids,2003,vol. 22,p. 153 - 173
[13]Organic Letters,2003,vol. 5,p. 2223 - 2226
[14]Bioscience, Biotechnology and Biochemistry,2004,vol. 68,p. 1888 - 1897
[15]Chemical Communications,2005,p. 2630 - 2632
[16]Cellular and Molecular Life Sciences,2006,vol. 63,p. 1912 - 1922
[17]Journal of the Chemical Society. Perkin Transactions 2 (2001),2000,p. 1187 - 1192
[18]Bioscience, Biotechnology and Biochemistry,2006,vol. 70,p. 1606 - 1615
[19]Nucleosides, nucleotides and nucleic acids,2008,vol. 27,p. 319 - 331
[20]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 1207 - 1211
[21]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 1276 - 1289
[22]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 3999 - 4008
[23]Journal of Biological Chemistry,2010,vol. 285,p. 473 - 482
[24]Journal of Biological Chemistry,2010,vol. 285,p. 13131 - 13141
[25]Journal of Biological Chemistry,2010,vol. 285,p. 15916 - 15922
[26]FEBS Journal,2010,vol. 277,p. 2654 - 2662
[27]Antimicrobial Agents and Chemotherapy,2010,vol. 54,p. 1590 - 1595
[28]Chemistry and Biology,2011,vol. 18,p. 966 - 975
[29]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 7175 - 7179
[30]Journal of Coordination Chemistry,2011,vol. 64,p. 3441 - 3453
[31]Organic and Biomolecular Chemistry,2012,vol. 10,p. 8941 - 8943
[32]The Enzymes, Bd. 5 <New York 1961> S. 159, 162,
[33]Inorganica Chimica Acta,2014,vol. 417,p. 163 - 170
[34]Chemical Communications,2014,vol. 50,p. 12037 - 12039
[35]Protein Science,2014,vol. 23,p. 1773 - 1779
[36]PLoS ONE,2015,vol. 10
[37]Journal of Biological Chemistry,2015,vol. 290,p. 24222 - 24236
[38]Inorganic Chemistry,2016,vol. 55,p. 9204 - 9211
[39]Patent: WO2018/85379,2018,A2 .Location in patent: Paragraph 00128; 00133; 00134; 00136; 00138; 00140-00142

4
[ 606-67-7 ]
[ 61-19-8 ]
[ 58-64-0 ]

Reference： [1]Journal of the American Chemical Society,1985,vol. 107,p. 8288 - 8289
[2]Organic and Biomolecular Chemistry,2006,vol. 4,p. 2278 - 2284

5
[ 61-19-8 ]
[ 131-99-7 ]
[ 58-64-0 ]
[ 56-65-5 ]

Reference： [1]Agricultural and Biological Chemistry,1988,vol. 52,p. 909 - 914
[2]Agricultural and Biological Chemistry,1988,vol. 52,p. 909 - 914
[3]Agricultural and Biological Chemistry,1988,vol. 52,p. 909 - 914
[4]Agricultural and Biological Chemistry,1988,vol. 52,p. 909 - 914

6
[ 61-19-8 ]
[ 58-64-0 ]
[ 56-65-5 ]
[ 1062-98-2 ]

Reference： [1]Tetrahedron Letters,1993,vol. 34,p. 4801 - 4804
[2]Tetrahedron Letters,1993,vol. 34,p. 4801 - 4804

7
[ 76947-02-9 ]
[ 5135-30-8 ]
[ 58-64-0 ]

Reference： [1]Journal of Organic Chemistry,1987,vol. 52,p. 1794 - 1801

8
[ 5135-30-8 ]
[ 58-64-0 ]

Reference： [1]Tetrahedron Letters,1984,vol. 25,p. 4055 - 4058

9
Morpholin-4-yl-phosphonic acid mono-{(3aR,4R,6R,6aR)-2-methoxy-6-[6-(4-methoxy-phenylamino)-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl} ester [ No CAS ]
[ 58-64-0 ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1981,vol. 100,p. 285 - 290

10
mTrNH(CH₂)2SpT tri-n-octylammonium salt [ No CAS ]
[ 58-64-0 ]
[ 30632-08-7 ]

Reference： [1]Tetrahedron,1989,vol. 45,p. 651 - 660

11
[ 20816-58-4 ]
[ 58-64-0 ]
[ 5959-90-0 ]

Reference： [1]Tetrahedron Letters,1990,vol. 31,p. 235 - 238

12
[ 58-64-0 ]
[ 56-65-5 ]
[ 5959-90-0 ]

Reference： [1]Agricultural and Biological Chemistry,1989,vol. 53,p. 615 - 624

13
[ 58-64-0 ]
[ 123746-61-2 ]

Reference： [1]Phosphorus, Sulfur and Silicon and the Related Elements,1990,vol. 51/52,p. 547 - 550

14
[ 58-64-0 ]
[ 61-19-8 ]

Yield	Reaction Conditions	Operation in experiment
	With nucleoside triphosphate diphosphohydrolase from Legionella pneumophila; In aq. buffer; at 37 - 99℃; for 0.25h;Enzymatic reaction;Kinetics;	The reaction mixture for the Lp1NTPDase inhibition assay contained 50 lL ADP (final concentration 500 lM) dissolved in assay buffer, 10 lL of test compound, and 30 lL of enzyme buffer in a reaction tube. The enzymatic reaction was initiated by adding 10 lL of enzyme solution to each test tube, carried out at 37Cfor 10 min and stopped by heating at 99C for 5 min. Then 100 lL of internal standard UMP (40 lM or 50lM) was added, 100 lL of the resulting solution was transferred to a CE vial and subjected to the CE.
	With SmNPP5;Enzymatic reaction;	SmNPP5 has additional promiscuity and has been shown to cleave substrates in addition to ADP. As a non-limiting example, SmNPP5 has been shown to cleave Ap3A (diadenosine triphosphate) into AMP and Pi (see e.g., FIG. 9A-FIG. 9C). As another non limiting example, SmNPP5 has been shown to cleave Ap4A (diadenosine tetraphosphate) into AMP and PPi (see e.g., FIG. 10A-FIG. 10C). Ap3A and Ap4A are both canonical ATPase inhibitors. Without wishing to be bound by theory, it is proposed that cleavage of Ap3 A or Ap4A by SmNPP5 can have an effect on coagulation, such as an anti-coagulation effect.

Reference： [1]Chemical and Pharmaceutical Bulletin,1982,vol. 30,p. 2926 - 2934
[2]Helvetica Chimica Acta,1983,vol. 66,p. 2454 - 2466
[3]Biochemical Pharmacology,2004,vol. 67,p. 1917 - 1926
[4]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 4363 - 4371
[5]Patent: WO2019/178526,2019,A1 .Location in patent: Paragraph 00196

15
[ 58-64-0 ]
[ 61-19-8 ]
[ 56-65-5 ]

Reference： [1]Chemistry Letters,1985,p. 985 - 988
[2]Chemistry Letters,1985,p. 985 - 988
[3]Chemistry Letters,1985,p. 985 - 988
[4]Journal of the American Chemical Society,1986,vol. 108,p. 169 - 173
[5]Phytochemistry,1996,vol. 42,p. 589 - 594

16
[ 58-64-0 ]
[ 64060-84-0 ]

Reference： [1]Carbohydrate Research,1982,vol. 111,p. 85 - 92
[2]Biochemistry,2010,vol. 49,p. 1404 - 1417

17
[ 58-64-0 ]
[ 56-65-5 ]

Reference： [1]Journal of the Chemical Society. Chemical communications,1991,p. 451 - 453
[2]Journal of the Chemical Society. Perkin transactions II,1991,p. 329 - 331
[3]Berichte der Bunsen-Gesellschaft,1980,vol. 84,p. 1055 - 1059
[4]Berichte der Bunsengesellschaft/Physical Chemistry Chemical Physics,1980,vol. 84,p. 1059 - 1062
[5]Berichte der Bunsengesellschaft/Physical Chemistry Chemical Physics,1984,vol. 88,p. 599 - 608
[6]Berichte der Bunsengesellschaft/Physical Chemistry Chemical Physics,1984,vol. 88,p. 599 - 608
[7]Bioscience, Biotechnology and Biochemistry,1998,vol. 62,p. 1594 - 1596
[8]Journal of the Chinese Chemical Society,2002,vol. 49,p. 961 - 963
[9]Journal of the American Chemical Society,2010,vol. 132,p. 3870 - 3878
[10]Chemical Communications,2011,vol. 47,p. 4472 - 4474
[11]Biochemistry,2010,vol. 49,p. 7733 - 7747
[12]Bioscience, Biotechnology and Biochemistry,2011,vol. 75,p. 1740 - 1745
[13]Molecular BioSystems,2011,vol. 7,p. 1863 - 1873
[14]RSC Advances,2016,vol. 6,p. 11815 - 11821
[15]Angewandte Chemie - International Edition,2019,vol. 58,p. 796 - 800
Angew. Chem.,2019,vol. 131,p. 806 - 810,5
[16]ChemBioChem,2019,vol. 20,p. 2961 - 2967

18
[ 56-65-5 ]
[ 61-19-8 ]
[ 58-64-0 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1982,vol. 30,p. 2926 - 2934
[2]Bulletin of the Chemical Society of Japan,1996,vol. 69,p. 765 - 774
[3]ACH - Models in Chemistry,1996,vol. 133,p. 365 - 388
[4]Biochemical Pharmacology,2004,vol. 67,p. 1917 - 1926
[5]Inorganic Chemistry,2016,vol. 55,p. 4864 - 4873

19
[ 56-65-5 ]
[ 61-19-8 ]
[ 5959-90-0 ]
[ 5542-28-9 ]
[ 58-64-0 ]

Reference： [1]Agricultural and Biological Chemistry,1989,vol. 53,p. 615 - 624

20
[ 56-65-5 ]
[ 58-64-0 ]
[ 482-67-7 ]

Reference： [1]Journal of the American Chemical Society,1995,vol. 117,p. 8031 - 8032

21
[ 58-64-0 ]
[ 23600-16-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1997,vol. 7,p. 1753 - 1756
[2]Bioorganic and Medicinal Chemistry Letters,2000,vol. 10,p. 2387 - 2389

22
[ 35094-46-3 ]
[ 58-98-0 ]
[ 58-64-0 ]
[ 79049-97-1 ]

Reference： [1]British Journal of Pharmacology,1996,vol. 117,p. 203 - 209

23
[ 56-65-5 ]
[ 61-19-8 ]
[ 66224-66-6 ]
[ 58-64-0 ]
[ 58-61-7 ]

Reference： [1]Chemistry Letters,1999,p. 125 - 126

24
[ 58-64-0 ]
adenylate-cyclase [ No CAS ]
[ 60-92-4 ]

Reference： [1]Journal of Biological Chemistry,1958,vol. 232,p. 1065,1072

25
[ 7732-18-5 ]
[ 56-65-5 ]
[ 58-64-0 ]

Reference： [1]Journal of the American Chemical Society,1953,vol. 75,p. 323
[2]Journal of the American Chemical Society,1953,vol. 75,p. 323
[3]Journal of the American Chemical Society,1953,vol. 75,p. 323

26
[ 61-19-8 ]
[ 56-65-5 ]
adenylate-kinase [ No CAS ]
[ 58-64-0 ]

Reference： [1]Methods in Enzymology,1955,vol. 2,p. 598

27
[ 56-65-5 ]
adenosine triphosphatase [ No CAS ]
myosin [ No CAS ]
[ 58-64-0 ]

Reference： [1]Handbuch der Physiologisch- und Pathologisch-Chemischen Analyse, 10. Aufl., Bd. 6, Tl. C <Berlin 1966> S. 439,
[2]Handbuch der Physiologisch- und Pathologisch-Chemischen Analyse, 10. Aufl., Bd. 6, Tl. C <Berlin 1966> S. 413,

28
[ 7732-18-5 ]
[ 56-65-5 ]
[ 61-19-8 ]
[ 58-64-0 ]

Reference： [1]Bulletin de la Societe de chimie biologique,1958,vol. 40,p. 759 - 765
[2]Bulletin de la Societe de chimie biologique,1958,vol. 40,p. 759 - 765
[3]Bulletin de la Societe de chimie biologique,1958,vol. 40,p. 759 - 765
[4]Bulletin de la Societe de chimie biologique,1958,vol. 40,p. 759 - 765

29
[ 56-65-5 ]
[ 58-61-7 ]
adenosine-kinase [ No CAS ]
[ 61-19-8 ]
[ 58-64-0 ]

Reference： [1]The Enzymes, Bd. 6 <New York 1962> S. 133,

30
[ 85-32-5 ]
[ 56-65-5 ]
guanylate-kinase [ No CAS ]
[ 58-64-0 ]
[ 146-91-8 ]

Reference： [1]Journal of Biological Chemistry,1965,vol. 240,p. 351 - 357

31
[ 58-64-0 ]
polymer metaphosphate [ No CAS ]
poly phosphate-kinase [ No CAS ]
[ 56-65-5 ]

Reference： [1]Biochimica et Biophysica Acta,1957,vol. 26,p. 294,295

32
[ 56-65-5 ]
[ 61-19-8 ]
[ 58-64-0 ]
[ 58-61-7 ]

Reference： [1]Bulletin of the Chemical Society of Japan,2000,vol. 73,p. 1805 - 1811

33
[ 56-65-5 ]
water [ No CAS ]
[ 58-64-0 ]

Reference： [1]Biochemical pharmacology,1996,vol. 51,p. 1453 - 1460

34
[ 56-65-5 ]
mevalonate 5-pyrophosphate [ No CAS ]
[ 358-71-4 ]
[ 58-64-0 ]

Reference： [1]Biological and Pharmaceutical Bulletin,2002,vol. 25,p. 302 - 306

35
[ 5959-90-0 ]
[ 60-92-4 ]
[ 61-19-8 ]
[ 58-64-0 ]
C₂₀H₂₉N₁₀O₁₇P₃ [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2004,vol. 2,p. 770 - 776

36
[ 5542-28-9 ]
[ 61-19-8 ]
[ 58-64-0 ]
[ 56-65-5 ]
C₁₅H₂₅N₅O₂₀P₄ [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2004,vol. 2,p. 770 - 776

37
[ 20816-58-4 ]
[ 58-64-0 ]
[ 5959-90-0 ]

Reference： [1]Journal of the American Chemical Society,2004,vol. 126,p. 9548 - 9549

38
[ 38168-82-0 ]
[ 58-64-0 ]
[ 820-11-1 ]
[ 56-65-5 ]

Reference： [1]Biochemical Pharmacology,2004,vol. 68,p. 1749 - 1756

39
[ 820-11-1 ]
[ 56-65-5 ]
[ 38168-82-0 ]
[ 58-64-0 ]

Reference： [1]Biochemical Pharmacology,2004,vol. 68,p. 1749 - 1756

40
[ 138-08-9 ]
[ 58-64-0 ]
[ 127-17-3 ]
[ 56-65-5 ]

Reference： [1]Journal of Chemical Thermodynamics,2003,vol. 35,p. 1809 - 1830

41
[ 127-17-3 ]
[ 56-65-5 ]
[ 138-08-9 ]
[ 58-64-0 ]

Reference： [1]Journal of Chemical Thermodynamics,2003,vol. 35,p. 1809 - 1830

42
[ 123-62-6 ]
[ 58-64-0 ]
C₁₆H₂₃N₅O₁₂P₂ [ No CAS ]

Reference： [1]Analytical Chemistry,2004,vol. 76,p. 2869 - 2877

43
[ 93-97-0 ]
[ 58-64-0 ]
C₂₄H₂₃N₅O₁₂P₂ [ No CAS ]

Reference： [1]Analytical Chemistry,2004,vol. 76,p. 2869 - 2877

44
[ 20816-58-4 ]
[ 58-64-0 ]

Reference： [1]Synthetic Communications,2006,vol. 36,p. 3393 - 3399

45
[ 58-64-0 ]
ADP-Ca-ADP [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With calcium chloride; In water;	ADP was dissolved at 100 mg/ml in DW and a half-molar amount of CaC12 dissolved at 100 mg/ml slowly dripped into the solution. The resultant ADP-Ca-ADP chelate was lyophilized.

Reference： [1]Patent: WO2007/131286,2007,A1 .Location in patent: Page/Page column 74

46
tert-butyloxycarbonyl-L-lysine-7-amino-3-methylcoumarin [ No CAS ]
[ 58-64-0 ]
N-tBoc-(L)lysine-ε-AMP-7-methylcoumarinamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
20.6%		Example 1: tBoc-LysAMP-AMC Synthesis and Characterization tBoc-Lys AMP-AMC was made as a modification of the adenosine 5'phosphoramidate synthesis method of Fu et al. (Chemistry Communications 2003 33:134-135). Under an argon atmosphere at room temperature, 0.25 mmol of tBoc-Lys- AMC (Bachem Biosciences Inc., King of Prussia, PA) and 0.12 mmol ADP (SigmaChemical Co., St. Louis, MO) were dissolved in 2 ml pyridine plus 0.6 ml trimethylsilyl chloride, added dropwise, and the resulting mixture was stirred for 2 days. The mixture was evaporated and 1 ml of 2M aqueous ammonia was added to hydrolyze the residue. Product was extracted with four 5 ml volumes of diethyl ether, evaporated to dryness, and dissolved in 1.5 ml isopropanol-2M aqueous ammonia-methanol (7:1:2). tBoc-LysAMP- AMC (yield = 20.6%) was purified twice by silica gel column chromatography using a 10 x 1 cm column. Peak material was analyzed by MALDI-MS and NMR. MALDI was performed on an Applied Biosystems Voyager System 6235 in negative ion mode using 3- hydroxypicolinic acid (observed mass = 733.79; calculated mass = 734.26). 31P, 13C and 1H NMR data were collected using a 15 mm probe with the compound in DMSO. 1NMR (50OmHz, DMSO-J15, 5O0C) delta = 10.93 (s, IH), 10.85 (s, IH), 8.47 (s, IH), 8.12 (s, IH), 7.81 (d, J=2.0 Hz, IH), 7.71 (d, J=8.5 Hz, IH), 7.53 (d, J=8.8 Hz, IH), 7.35-7.44 (m, 2H), 7.27 (d, J=7.6 Hz, IH), 7.10-7.16 (m, IH), 6.25 (d, J=I.2 Hz, IH), 5.89 (d, J=5.4 Hz, IH), 5.57-5.62 (m, IH), 4.55-4.59 (m, IH), 4.18-4.21 (m, IH), 4.07-4.21 (m, IH), 4.02-4.05 (m, IH), 3.83-3.88 (m, IH), 3.74-3.80 (m, IH), 2.72-2.77 (m, IH), 2.66-2.70 (m, IH), 2.36 (d, J= 4.2 Hz, 3H), 1.64-1.70 (m, IH), 1.57-1.61 (m, IH), 1.33 (d, J=13.9 Hz, 9H), 1.23- 1.25 (m, IH), 1.00 (d, J= 6.1 Hz, 3H); 13C NMR (hmqc, DMSO-rf*, 5O0C, partial) delta = EPO <DP n="14"/>153.3, 126.5, 116.0, 112.7, 106.2, 87.5, 84.4, 74.5, 71.3, 64.3, 41.5, 40.3, 31.6, 28.8, 28.6, 28.1, 26.0, 18.6; 31P NMR (30OmHz, DMSO-J6) delta = 2.66.

Reference： [1]Patent: WO2006/44918,2006,A2 .Location in patent: Page/Page column 12-13

47
[ 102-82-9 ]
[ 58-64-0 ]
[ 90290-56-5 ]

Yield	Reaction Conditions	Operation in experiment
	In ethanol;	ADP (Bu3NH+)2, AMP (Bu3NH+)2 and UMP (Bu3NH+)2 were prepared from the corresponding free acid and tributylamine (Bu3N; 2 eq) in EtOH

Reference： [1]Patent: US2006/287271,2006,A1 .Location in patent: Page/Page column 7-8

48
[ 61-19-8 ]
[ 58-64-0 ]
[ 56-65-5 ]
[ 58-61-7 ]

Reference： [1]Nucleosides, nucleotides and nucleic acids,2008,vol. 27,p. 872 - 875

49
[ 100849-37-4 ]
[ 58-64-0 ]
C₁₀⁽¹³⁾C₆H₂₀N₆O₉P₂ [ No CAS ]

Reference： [1]Analytical Chemistry,2008,vol. 80,p. 9508 - 9516

50
[ 62-53-3 ]
[ 58-64-0 ]
[ 58430-79-8 ]

Reference： [1]Analytical Chemistry,2008,vol. 80,p. 9508 - 9516

51
tetradecameric chaperonin GroEL [ No CAS ]
[ 58-64-0 ]
GroEL(ADP)14 chaperonin complex [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2009,vol. 131,p. 1452 - 1459

52
[ 6556-12-3 ]
[ 56-65-5 ]
[ 10345-04-7 ]
[ 58-64-0 ]

Reference： [1]Journal of Biological Chemistry,2010,vol. 285,p. 2902 - 2910

53
[ 56-65-5 ]
[ 71-00-1 ]
[ 107-95-9 ]
[ 305-84-0 ]
[ 58-64-0 ]

Reference： [1]Journal of Biological Chemistry,2010,vol. 285,p. 9346 - 9356

54
6-amino-2-{2-[bis-(2-amino-ethyl)-amino]-ethylamino}-3-methyl-5-nitroso-3H-pyrimidin-4-one [ No CAS ]
[ 58-64-0 ]
[ 1286791-75-0 ]

Reference： [1]Chemical Communications,2011,vol. 47,p. 2814 - 2816

55
[ 58-64-0 ]
[ 73116-35-5 ]

Yield	Reaction Conditions	Operation in experiment
	With 3Na(1+)*P(18)O4(3-)=Na3P(18)O4;succinyl-CoA synthetase; at 20℃; for 0.05h;pH 8.1;Enzymatic reaction; Glycylglycine buffer;	Example 1: Synthesis of [gamma18O3]ATP Bacterial succinyl-CoA synthetase (an ammonium sulphate suspension) was diluted in 100 mM glycylglycine buffer, pH 8.1 containing 10 mM MgC12. Based on leading experiments for the synthesis of (gamma32P)ATP the reaction with Na3P18O4 was carried out with 1 or 2 enzyme Units per 50 mul total volume of the reaction solution which includes (final concentrations of) 100 mM glycylglycine buffer (pH 8.1), 10 mM MgCl2, 2.5 mM ADP, 100 muM succinyl-CoA. The reaction was started by the addition of 50 nmol Na3P18O4 and left at RT for 3 min. Reaction stop was by addition of 10 mul I N HC1 and samples were stored at 4C until purification by HPLC. The samples were purified by HPLC-system using a C2/C18-column (muRPC) preequilibrated with Triethylamine/acetic acid buffer (pH 7.0) (buffer A) containing 4 mM Triethylamine, 10 mM acetic acid, 0.25% methanol. The column effluent was monitored by spectrophotometrically due to the adsorption maxima of ATP and ADP purine rings at at 258 nm wavelength. Na3P18O4-samples diluted with bidest. water up to 2 ml were injected through a sample loop and the column continuously washed with buffer A until stable baseline was reached. Subsequently, elution of ATP and thereby separation from ADP in the sample was achieved by Triethylamine/acetic acid buffer (pH 5.5) (buffer B) containing 24 mM Triethylamine, 100 mM acetic acid, 30% methanol. A typical elution profile for the ATP separation is given in the Figure below. It shows start of the elution at 9% buffer B and upon application of the buffer gradient ATP gets eluted at 19% buffer B (6 ml elution volume). For determining crop of such [gamma18O3]ATP purification, parallel runs under identical conditions were performed with 16O-ATP/ADP standards. Upon 20 repeats of the HPLC-purification runs yields of 100-125 nmol [gamma18O3]ATP were obtained, respectively. The [gamma18O3]ATP fraction being in 80 mM Triethylamine-acetate buffer was further treated to remove the volatile buffer by vacuum centrifugation (Speedvac) until dryness. Then the sample was dissolved in 300mul bidest. water, deep frozen and finally lyophilized under high vacuum. The [gamma18O3]ATP preparations were kept at -80C until use, e.g. as the cosubstrate for protein phosphorylation.
	With 3Na(1+)*P(18)O4(3-)=Na3P(18)O4; succinyl-CoA synthetase; magnesium chloride; at 20℃; for 0.05h;pH 8.1;Enzymatic reaction; glycylglycine buffer;	Bacterial succinyl-CoA synthetase (an ammonium sulphate suspension) was diluted in 100 mM glycyl glycine buffer, pH 8.1 containing 10 mM MgCl2. Based on leading experiments for the synthesis of (gamma32Rho)AlphaTauRho, the reaction with Na3P18O4 was carried out with 1 or 2 enzyme Units per 50 mu total volume of the reaction solution which includes (final concentrations of) 100 mM glycylglycine buffer (pH 8.1), 10 mM MgCl2, 2.5 mM ADP, 100 muMu succinyl-CoA. The reaction was started by the addition of 50 nmol Na3P18O4 and left at RT for 3 min. Reaction stop was by addition of 10 mu1 1 N HC1 and samples were stored at 4C until purification by HPLC.The samples were purified by HPLC-system using a C2/C18-column ^RPC) preequiiibrated with Triethylamine/acetic acid buffer (pH 7.0) (buffer A) containing 4 mM Triethylamine, 10 mM acetic acid, 0.25% methanol. The column effluent was monitored by spectrophotometrically due to the adsorption maxima of ATP and ADP purine rings at at 258 nm wavelength. Na3P18O4-samples diluted with bidest. water up to 2 ml were injected through a sample loop and the column continuously washed with buffer A until stable baseline was reached. Subsequently, elution of ATP and thereby separation from ADP in the sample was achieved by Triethylamine/acetic acid buffer (pH 5.5) (buffer B) containing 24 mM Triethylamine, 100 mM acetic acid, 30% methanol. A typical elution profile for the ATP separation is given in the Figure below. It shows start of the elution at 9% buffer B and upon application of the buffer gradient ATP gets eluted at 19% buffer B (6 ml elution volume). For determining crop of such [gamma18O3]AlphaTauRho purification, parallel runs under identical conditions were performed with 16O-ATP/ADP standards. Upon 20 repeats of the HPLC-purification runs yields of 100-125 nmol [gamma18O3]AlphaTauRho were obtained, respectively.The [gamma18O3]ATP fraction being in 80 mM Triethylamine-acetate buffer was farther treated to remove the volatile buffer by vacuum centrifugation (Speed vac) until dryness. Then the sample was dissolved in 300mu1 bidest. water, deep frozen and finally lyophilized under high vacuum. The [gamma18O3]AlphaTauRho preparations were kept at -80C until use, e.g. as the cosubstrate for protein phosphorylation.

Reference： [1]Patent: EP2327678,2011,A1 .Location in patent: Page/Page column 7-8
[2]Patent: WO2011/64289,2011,A1 .Location in patent: Page/Page column 15

56
[ 56-65-5 ]
[ 81410-37-9 ]
[ 81410-35-7 ]
[ 76991-64-5 ]
[ 58-64-0 ]

Reference： [1]Antiviral Research,2010,vol. 87,p. 345 - 352

57
[ 492-62-6 ]
[ 56-65-5 ]
[ 58-64-0 ]
[ 59-56-3 ]

Yield	Reaction Conditions	Operation in experiment
	With recombinant galactokinase from Streptococcus pneumoniae TIGR4; magnesium chloride; at 45℃; for 3h;pH 8;aq. buffer; Enzymatic reaction;Kinetics;	General procedure. The activity of recombinant GalKSpe4 toward Gal, Glc, N-acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc) was assayed in a cocktail containing 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 5 mM <strong>[56-65-5]ATP</strong> and proper amount of GalKSpe4 at 45 C for 3 h. The reaction was terminated by boiling the mixture for 5 min followed by centrifugation. The supernatant was analyzed by normal phase silica gel thin-layer chromatography with the phase being n-butanol/acetic acid/water (2:1:1, v/v/v).

Reference： [1]Carbohydrate Research,2011,vol. 346,p. 2421 - 2425

58
[ 3646-73-9 ]
[ 56-65-5 ]
[ 58-64-0 ]
[ 59-56-3 ]

Yield	Reaction Conditions	Operation in experiment
	With recombinant galactokinase from Streptococcus pneumoniae TIGR4; magnesium chloride; at 45℃; for 3h;pH 8;aq. buffer; Enzymatic reaction;Kinetics;	The activity of protein GalKSpe4 toward Gal was assayed as described before11 with a little modification. Briefly, the reaction mixture containing Gal (8 mM), <strong>[56-65-5]ATP</strong> (10 mM), MgCl2 (5 mM), and GALK (6 muM) in Tris-HCl buffer (20 mM, pH 8.0) was incubated at 45 C for 180 min. The reducing sugar consumed in this reaction was quantified by the DNS method with d-Gal as standard.26 The effects of temperature (25-50 C) and pH (3.0-11.0) on the activity of GalKSpe4 were determined using Gal as the substrate. Kinetic data were obtained by determining the slope of linear phase of the progress curve over 2 min in 30 s intervals and then by calculating the kinetic parameters as described by Yang et 12

Reference： [1]Carbohydrate Research,2011,vol. 346,p. 2421 - 2425

59
[ 10036-64-3 ]
[ 56-65-5 ]
[ 28446-21-1 ]
[ 58-64-0 ]

Yield	Reaction Conditions	Operation in experiment
	With recombinant galactokinase from Streptococcus pneumoniae TIGR4; magnesium chloride; at 45℃; for 3h;pH 8;aq. buffer; Enzymatic reaction;	General procedure. The activity of recombinant GalKSpe4 toward Gal, Glc, N-acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc) was assayed in a cocktail containing 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 5 mM <strong>[56-65-5]ATP</strong> and proper amount of GalKSpe4 at 45 C for 3 h. The reaction was terminated by boiling the mixture for 5 min followed by centrifugation. The supernatant was analyzed by normal phase silica gel thin-layer chromatography with the phase being n-butanol/acetic acid/water (2:1:1, v/v/v).

Reference： [1]Carbohydrate Research,2011,vol. 346,p. 2421 - 2425

60
[ 72-87-7 ]
[ 56-65-5 ]
[ 92283-18-6 ]
[ 58-64-0 ]

Yield	Reaction Conditions	Operation in experiment
	With recombinant galactokinase from Streptococcus pneumoniae TIGR4; magnesium chloride; at 45℃; for 3h;pH 8;aq. buffer; Enzymatic reaction;Kinetics;	General procedure. The activity of recombinant GalKSpe4 toward Gal, Glc, N-acetylgalactosamine (GalNAc) and N-acetylglucosamine (GlcNAc) was assayed in a cocktail containing 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 5 mM <strong>[56-65-5]ATP</strong> and proper amount of GalKSpe4 at 45 C for 3 h. The reaction was terminated by boiling the mixture for 5 min followed by centrifugation. The supernatant was analyzed by normal phase silica gel thin-layer chromatography with the phase being n-butanol/acetic acid/water (2:1:1, v/v/v).

Reference： [1]Carbohydrate Research,2011,vol. 346,p. 2421 - 2425

61
[ 1350980-53-8 ]
[ 56-65-5 ]
[ 1350980-54-9 ]
[ 5959-90-0 ]
[ 58-64-0 ]

Yield	Reaction Conditions	Operation in experiment
		Carried out as follows: (i) 5 mM aqueous <strong>[56-65-5]ATP</strong> ((1) retention time 3.93 min) was stirred with excess sodium periodate to give ribose-oxidised dialdehyde-<strong>[56-65-5]ATP</strong> ((2) 4.06 min); (ii) The pH of the mixture was adjusted to 4.5 and a concentratedsolution of biotin-LC-hydrazide (3) in DMSOwas slowly added over 30 min, with vigorous stirring. HPLC analysis after a further hour showed the presence of biotin-LC-<strong>[56-65-5]ATP</strong> (4) at 3.69 min; (iii) the periodate was quenched with sodium borohydride (3.87 min) and the Tris-HCl added to 50 mM, pH 8.0; (iv) finally, Llysine (to 2 mM), MgCl2 (10 mM), ZnCl2 (160 lM), LysU (10 lM), inorganic pyrophosphatase (Sigma-Aldrich; 6 U/mL) was added in sequence and the mixture warmed to 37 C. Aqueous <strong>[56-65-5]ATP</strong> (to 6 mM) was then added in four portions over the period of 1 h and resulting mixture left for a further hour to give biotin-LC-Ap4A (6) as the majority product (4.24 min); (v) purification was easilycarried out by SOURCE-15Q/TEAB ion exchange HPLC as previously described24 and combined product fractions lyophilised to a highly hydroscopic, white crystalline solid, before storage at -20 C. Major side products from this reaction included Ap3A, ADP and 4. Compound 5 was identified by ESI-MS: [M-H]-1185.7 m/z, expected (C36H52N15O21P4S-) 1186.2 m/z and 31P NMR (202 MHz,D2O, 21500x) delta -11.63 (2P, m, Jalphabeta/deltagamma 22.2, Palpha,delta), -23.16 (1P, d, Jgammadelta 18.2, Pgamma), -23.28 (1P, d, Jbetaalpha 24.2, Pbeta), purity confirmed as >95% by HPLC.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2011,vol. 21,p. 7175 - 7179

62
[ 41708-91-2 ]
[ 58-64-0 ]
[ 56-65-5 ]

Reference： [1]Biological and Pharmaceutical Bulletin,2012,vol. 35,p. 1191 - 1196

63
[ 7659-75-8 ]
[ 58-64-0 ]
P1,P3-diadenosine-5',5'-triphosphate triammonium salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: To a solution of nucleoside 5?-phosphoropiperidates (1-4, 0.1mmol) in N-methylpyrrolidone (2mL) were added NDPs (0.05mmol, the content of Bu3N was 2.0equiv) and DCI (0.25mmol). The reaction was stirred at 40C for 8h. Then, diethyl ether (20mL) was added into the solution, and the resulting white precipitate was collected by centrifuge. The crude products were dissolved in deionized H2O (1mL) and loaded onto an ion exchange gel column. Elution with NH4HCO3 buffer (linear gradient 0.2-0.5M), combination of appropriate fractions, and lyophilization gave Np3N?s as the ammonium salts. Passage of the solution of the ammonium salts in deionized H2O through a bed of Dowex 50W-X8 ion exchange resin (Na+ form) and lyophilization afforded dinucleoside triphosphate trisodium salts (16-18) as white solids.

Reference： [1]Tetrahedron,2014,vol. 70,p. 4500 - 4506

64
[ 58-64-0 ]
Piperidin-1-yl-phosphonic acid mono-[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl] ester [ No CAS ]
P1-adenosine-5'-P3-guanosine-5'-triphosphate triammonium salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: To a solution of nucleoside 5?-phosphoropiperidates (1-4, 0.1mmol) in N-methylpyrrolidone (2mL) were added NDPs (0.05mmol, the content of Bu3N was 2.0equiv) and DCI (0.25mmol). The reaction was stirred at 40C for 8h. Then, diethyl ether (20mL) was added into the solution, and the resulting white precipitate was collected by centrifuge. The crude products were dissolved in deionized H2O (1mL) and loaded onto an ion exchange gel column. Elution with NH4HCO3 buffer (linear gradient 0.2-0.5M), combination of appropriate fractions, and lyophilization gave Np3N?s as the ammonium salts. Passage of the solution of the ammonium salts in deionized H2O through a bed of Dowex 50W-X8 ion exchange resin (Na+ form) and lyophilization afforded dinucleoside triphosphate trisodium salts (16-18) as white solids.

Reference： [1]Tetrahedron,2014,vol. 70,p. 4500 - 4506

65
[ 58-64-0 ]
[ 36703-14-7 ]

Yield	Reaction Conditions	Operation in experiment
	With dihydrogen peroxide; acetic acid; In water; at 20℃; for 312h;	0029] To a 500 mL four-necked flask were added 8.54 g of adenosine 5?-diphosphate with a product code of 590-29413,commercialized by Wako Pure Chemical Industry, Ltd., Osaka, Japan, 28 mL of refined water, and 84 mL of acetic acid.While stirring at ambient temperature, the resulting mixture was then added with 28 mL of 30% hydrogen peroxidesolution over two minutes, and further stirred at ambient temperature for 13 days. Thereafter, the resulting mixture wasadmixed with 280 mL of acetone over 20 min under ice-chilling conditions, and further stirred for one hour. The resultingreaction product was collected by suction filtration and washed with 40 mL of acetone, followed by drying the resultingsolids in vacuo in a desiccator. Then, 5.8 g of the solids was dissolved in 20 mL of water and admixed with 116 mL ofacetone to effect crystallization. The obtained crystals were collected by suction filtration to obtain 4.76 g of 5?-adenosinediphosphate N1-oxide, which was then purified on column chromatography to obtain 5?-adenosine diphosphate N1-oxidewith a purity of 98% or higher.[0030] 5?-Adenosine triphosphate N1-xide with a purity of 98% or higher was obtained similarly as in the above procedureexcept for replacing the above adenosine 5?-diphosphate with adenosine 5?-triphosphate with a product code ofP0756L, commercialized by New England Biolabs Japan Inc., Tokyo, Japan.

Reference： [1]Patent: EP2801348,2014,A1 .Location in patent: Paragraph 0029

66
[ 58-64-0 ]
[α-(32)P]guanosine 5'-triphosphate [ No CAS ]
c[G(2'-5')α32pA(3'-5')p] [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With DL-dithiothreitol; full length cyclic GMP-AMP synthase; sodium chloride; magnesium chloride; dsDNA; In glycerol; at 37℃; for 0.666667h;Enzymatic reaction;Kinetics; Catalytic behavior; Mechanism;	Purified recombinant full length (fl, amino acids 1-507) and truncated (tr, amino acids 147-507) murine cGAS, including truncated mutant versions 1-6, were incubated in 20 mu, reactions containing: 1 muMu cGAS, 3.3 muMu dsDNA, 5 mM MgCl2, 150 mM NaCl, 20 mM Tris- HCl, pH 7.5 at 25C, 1 mM DTT, 10% glycerol, 1 mM each of nucleotides (typically ATP and GTP), and a32P or gamma32Rho radiolabeled NTPs or dNTPs at 37C for 40 min. Reactions were stopped by addition of 20 of 50 mM EDTA. 2 mu^of reaction solution was spotted onto high- performance TLC plates (HPTLC silica gel, 60 A pores, F254, 10x10 cm, cat 1.05628.0001, EMD Millipore) and products were separated with Solvent 1 (NH4HC03:C2H5OH:H20 [0.2 M:30%:70%], w:v:v) or 2 (NH4HC03:C2H5OH:H20 [0.025 M:30%:70%], w:v:v) at 25 C for 1 h. Reaction products were visualized by UV (254 nm) and phosphorimaging (Typhoon FLA 9500, GE Healthcare). Images were processed using Adobe Photoshop and Illustrator CS5. The TLC conditions used were largely based on a protocol established to separate 3 ',5' cAMP (Higashida et al, 2012).

Reference： [1]Patent: WO2014/179335,2014,A1 .Location in patent: Paragraph 0009; 0284; 0313

67
[ 85-32-5 ]
[ 56-65-5 ]
[ 58-64-0 ]
[ 146-91-8 ]

Reference： [1]Small,2015,vol. 11,p. 5844 - 5850

68
[ 58-64-0 ]
[ 146-91-8 ]
[ 56-65-5 ]
[ 86-01-1 ]

Reference： [1]Small,2015,vol. 11,p. 5844 - 5850

69
phosphoenolpyruvate [ No CAS ]
[ 58-64-0 ]
[ 57-60-3 ]
[ 56-65-5 ]

Reference： [1]Journal of Biological Chemistry,2016,vol. 291,p. 9244 - 9256

70
[ 66-71-7 ]
terbium(III) nitrate [ No CAS ]
[ 58-64-0 ]
C₁₂H₈N₂*Tb⁽³⁺⁾*C₁₀H₁₂N₅O₁₀P₂^(3-) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In aq. buffer; at 20℃; for 3h;	1 mL of 1 mL of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer (100 mM, pH 7.4) containing 3 mM adenosine diphosphate (ADP) was added 1 mL of 3 mM Tb (NO3)3Aqueous solution, and then an aqueous solution of 2 mL of phenanthroline (Phen) at a concentration of 1.5 mM was added. The mixed solution was stirred at room temperature for 3 h and centrifuged at 10000 rpm for 20 min. The precipitate was washed with deionized water to remove unreacted reagent, centrifuged, The wash was repeated three times with deionized water. Finally, the precipitate was dried in an oven at 70 C, dried and stored in a desiccator

Reference： [1]Patent: CN103554142,2016,B .Location in patent: Paragraph 0030; 0031

71
[ 53-84-9 ]
[ 1094-61-7 ]
[ 58-64-0 ]
[ 58-61-7 ]

Yield	Reaction Conditions	Operation in experiment
	With water; zirconium(IV) oxide; at 80℃; for 48h;	(0117) A 10-mL vial was loaded with 0.33 g of NAD+, 0.29 g of zirconium dioxide (Zr02) . The powders were dissolved/dispersed with 9.5 mL of distilled water, and the mixture was heated at 80 C for 48 h. Zr02 was removed by centrifugation (10,000 rpm for 30 min) using 29x32x25-cm HSCEN-204 centrifuge. (0118) The 31P-NMR demonstrated a small peak at -11.15 ppm, attributed to NAD+, a peak at -0.03 ppm attributed to beta- nicotinamide mononucleotide, a peak at 0.09 ppm attributed to adenosine, and two peaks at 0.027 and 0.3 ppm, attributed to the two P atoms of adenosine diphosphate (ADP) .

Reference： [1]Patent: WO2017/145151,2017,A1 .Location in patent: Page/Page column 28

72
[ 58-64-0 ]
[ 2793-06-8 ]

Yield	Reaction Conditions	Operation in experiment
	With 5?-adenosylcobalamin; full-length enzyme NrdJd-wt from Stackebrandtia nassauensis; 2'-deoxyguanosine 5'-triphosphate; magnesium chloride; Cleland's reagent; In aq. buffer; at 20℃;Enzymatic reaction;Kinetics;	General procedure: Specific enzyme activities were determined by measurement of the conversion of NDP to dNDP, catalyzed by the enzyme in the presence of different dNTPs as allosteric effectors. All enzymatic assays were performed in triplicates. Under standard conditions the assay contains 50 mmol liter-1 Tris (pH 8.0), 20 mmol liter-1 MgCl2, 50 mmol liter-1 DTT, 1.0 mmol liter-1 dATP, 2.0 mmol liter-1 CDP, 5.0 mumol liter-1 AdoCl, and between 2 and 5 mumol liter-1 enzyme ( 0.2-0.5 mg ml-1). In effector titration experiments, a concentration range from 4 to 1000 mumol liter-1 was applied, including a measurement without effector. In the four substrate assays, 0.5 mmol liter-1 of each substrate (ADP, CDP, GDP, UDP) were applied with 0.5 mmol liter-1 of the tested effector. The assays, performed in 50-mul scale, were incubated 15 or 30 min at room temperature and stopped by addition of 50 mul methanol. After addition of 200 mul water, the samples were analyzed via HPLC. 20 mul of thesample were injected onto a C18 column and run with the followingbuffer: 50 mmol liter-1 potassium Pi (pH 7.5), 10% (v/v) methanol, 0.25% (v/v) tetrabutylammonium hydroxide. The buffer was prepared with KH2PO4 by setting the pH value with KOH. The analytes were eluted in a linear gradient of methanol from 10 to 30% (v/v).

Reference： [1]Journal of Biological Chemistry,2017,vol. 292,p. 19044 - 19054

73
[ 56-45-1 ]
[ 56-65-5 ]
[ 407-41-0 ]
[ 58-64-0 ]

Reference： [1]Journal of Biological Chemistry,2018,vol. 293,p. 6147 - 6160

74
[ 56-65-5 ]
hydrogenphosphate [ No CAS ]
[ 58-64-0 ]

Reference： [1]Chemistry - A European Journal,2018,vol. 24,p. 10745 - 10755

75
[ 56-65-5 ]
[ 58-64-0 ]
[ 1062-98-2 ]

Yield	Reaction Conditions	Operation in experiment
	With (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; nicotinamide phosphoribosyltransferase; water; at 37℃;Enzymatic reaction;Kinetics;	A calibration curve for adenosine 5'-tetraphosphate (Ap4) (Jena Bioscience) was prepared in 200 mu^ of 0.5 M perchloric acid (PC A) and 100 mM ammonium formate at Ap4 concentrations of 0.04 muMu, 0.08 muMu, 0.16 muMu, 0.3 muMu, 0.625 muMu, 1.25 muMu, 2.5 muMu, 6.25 muMu, 12.5 muMu, 25 muMu, 62.5 muMu, 125 muMu, 250 muMu, and 500 muMu. Calibration curve and study samples were run on an Accela HPLC/Thermo Scientific triple quadrupole mass spectrometer by positive electrospray ionization. 5 muL samples were injected onto a 3 x 50 mm, 3 muiotaeta Hypercarb column and separated using a linear gradient from 98% A (10 mM ammonium bicarbonate, pH 9.5) and 2% B (acetonitrile (ACN)) to 5% A and 95% B at 6.4 minutes at 0.6 mL/min. Multiple reaction monitoring was used to monitor transitions for Ap4 (m/z 588 136) and 13C1015N5-<strong>[56-65-5]ATP</strong> (m/z 523 -> 146) as an internal standard. Linear calibration curves were obtained using Xcalibur software to quantitate Ap4 in biological samples. Inorganic phosphate (Pi) was assayed using the PiColorLock Gold phosphate detection reagent (Innova Biosciences). (0193) [00148] To test the effects of NAMPT inhibitors on AP4 formation, human NAMPT (200 nM) was incubated with <strong>[56-65-5]ATP</strong> (2 mM) and vehicle (1% DMSO) or one of the NAMPT inhibitors FK- 866, CHS-828, or GNI-50 (1 muMu each) for increasing times at 37 C in TMD buffer. Samples (50 mu) were removed at the indicated times and quenched with 50 mu of 1M perchloric acid (PCA) and submitted for LC MS/MS to detect ADP and Ap4. Another sample (80 muL) was removed, frozen and subsequently assayed for Pi using the Pi ColorLock Gold assay kit. [00149] As described above, ADP, Pi, and Ap4 concentrations were measured after incubating NAMPT with <strong>[56-65-5]ATP</strong> and a NAMPT inhibitorsFK-866, CHS-828, or GNI-50. Surprisingly, these NAMPT inhibitors not only differentially modulated Ap4 formation, but this effect did not have a direct correlation with NTPase modulatory activity as observed through NAMPT' s <strong>[56-65-5]ATP</strong>ase activity. Incubation of human NAMPT (200 nM) with <strong>[56-65-5]ATP</strong> (2 mM) produced a time-dependent increase of Ap4 formation (1.04 muMu Ap4 per hr) (see FIG. 4C). The presence of NAMPT inhibitor FK-866 (at 1 muMu) had essentially no impact on Ap4 production (0.88 muMu Ap4 per hr). However, the NAMPT inhibitors CHS-828 and GNI-50 were markedly different from each other and from FK-866 with respect to their impact on NAMPT-mediated Ap4 production (see FIG. 4C). CHS-828 (1 muMu) nearly abolished Ap4 generation (0.88 muMu per hr), while GNI-50 stimulated Ap4 production approximately 1 9-fold (1.93 muMu per hr). Table 2 shows the impact of the NAMPT inhibitors on ADP, P and Ap4 formation. Notably, although FK-866 had the largest impact on ADP production (a 5.39-fold increase in ADP production as compared to vehicle control), it resulted in less than half the Ap4 of GNI-50. Moreover, Ap4 decreased with FK-866 as compared to vehicle control but increased with GNI-50 as compared to vehicle control. Table 2: Impact of NAMPT inhibitors on ADP, P;, and Ap4 formation by NAMPT (0194) (0195) [00150] The values in Table 4represent the mean production rates of ADP, Pi, or Ap4, or calculated values using those production rates, in muMu/hr. Values in parentheses represent standard deviations. Pi + Ap4 is the sum of Pi and Ap4 production rates, which corresponds to the ADP value if the Pi liberated during Ap4 hydrolysis has only two possible fates: free Pi and Ap4. ADP/(Pi + Ap4) is the ratio between ADP formation and combined Pi and Ap4 formation.

Reference： [1]Patent: WO2018/85379,2018,A2 .Location in patent: Paragraph 00147-00150

76
[ 58-64-0 ]
[ 14265-44-2 ]
[ 61-19-8 ]

Yield	Reaction Conditions	Operation in experiment
	With [D]-sodium hydroxide In aq. phosphate buffer; water-d2 at 37℃;

Reference： [1]Gu, Jinlou; Li, Chunzhong; Li, Ke; Yang, Jian [Angewandte Chemie - International Edition, 2020, vol. 59, # 51, p. 22952 - 22956][Angew. Chem., 2020, vol. 132, # 51, p. 23152 - 23156,5]

Same Skeleton Products

Related Products

Historical Records

Similar Product of
[ 58-64-0 ]

A143436[ 20398-34-9 ]

xSodium ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl diphosphate

Reason: Free-salt

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 58-64-0 ] {[proInfo.proName]}

Quality Control of [ 58-64-0 ]

Related Doc. of [ 58-64-0 ]

Product Details of [ 58-64-0 ]

Calculated chemistry of [ 58-64-0 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 58-64-0 ]

Application In Synthesis of [ 58-64-0 ]

[ 58-64-0 ] Synthesis Path-Upstream 1~1

[ 58-64-0 ] Synthesis Path-Downstream 1~76

Similar Product of [ 58-64-0 ]

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Similar Product of
[ 58-64-0 ]